Following this, the combination of lapatinib (1500 mg/day) and tri-weekly paclitaxel (175 mg/m2) as first-line therapy was evaluated in a Phase III study, in which 579 HER2-negative or unknown, advanced or recurrent breast cancer patients were enrolled [15]. This evidence concerns the gene ERBB2 and breast carcinoma.